Alexza Pharmaceuticals, Inc.

Fontem Holdings 1 B.v.

Alexza Molecular Delivery Corporation

Fontem Holdings I B.v.

Wensley, Martin

Lloyd, Peter

Hufford, Michael

Peter Lloyd

Martin J Wensley

Craig C Hodges

Ron L Hale

Joshua D Rabinowitz

Daniel J Myers

Daniel David Rogers

Daniel Mufson

Jeffrey Alan McKinney

Amy Tsai Lu

Reynaldo J Quintana

Soonho Song

Alejandro C Zaffaroni

Michael R Hufford

Dennis Solas

Curtis Peter Tom

Krishnamohan Sharma

Mingzu Lei

Stephen D Cross

Patrik Munzar

Matthew D Stracker

Jeffrey Williams

Martin Wensley

Michael Hufford

A device for generating a condensation aerosol includes vaporization chamber having an upstream first inlet and a downstream outlet. A tube supplies liquid to a heater in the vaporization chamber. The liquid is pumped out of the tube and onto the heater, which vaporizes the liquid. Air flows from inlets through the vaporization chamber, and generally perpendicular to the tube. The vaporized liquid is entrained in the air, forming a condensation aerosol having a particle size in a selected range. A second inlet provides a substantially laminar flow of air into the airflow path, wherein the second inlet is downstream of the heater; and the device capable of changing air flow in the vaporization chamber to change the particle size of the condensation aerosol and/or to change the amount of visible vapor emitted from the device.

Electronic vaporization devices

Inhalation delivery of aerosols containing small particles is described. Specifically, it relates to a device that forms drug containing aerosols for use in inhalation therapy. In a device aspect of the present disclosure, a device for delivering drug containing aerosols for inhalation therapy is provided. The device includes a housing and an airway that has a gas/vapor mixing airway. The airway further includes a subassembly, which has a metallic substrate coated on its surface with a composition comprising a drug.

Aerosol forming device for use in inhalation therapy

A device for generating a condensation aerosol includes (a) vaporization chamber having an upstream first inlet and a downstream outlet; (b) a heater element in the vaporization chamber between the upstream first inlet and the downstream outlet; (c) an airflow path in fluid communication with the vaporization chamber, wherein the airflow path comprises a second inlet configured to permit a substantially laminar flow of air into the airflow path, wherein the second inlet is downstream of the heater element; and (d) the device having components or apparatus on or in the device for changing air flow in the vaporization chamber. Changing the air flow in the vaporization chamber may be used to change the particle size of a condensation aerosol produced in the vaporization chamber, and/or to change the amount of visible vapor emitted from the device.

Methods and devices for modulating air flow in delivery devices

The present invention provides novel condensation aerosols for the treatment of disease and/or intermittent or acute conditions. These condensation aerosols have little or no pyrolysis degradation products and are characterized by having an MMAD of between 1-3 microns. These aerosols are made by rapidly heating a substrate coated with a thin film of drug having a thickness of between 0.05 and 20 &#x3bc;m, while passing a gas over the film, to form particles of a desirable particle size for inhalation. Kits comprising a drug and a device for producing a condensation aerosol are also provided. The device contained in the kit typically, has an element for heating the drug which is coated as a film on the substrate and contains a therapeutically effective dose of a drug when the drug is administered in aerosol form, and an element allowing the vapor to cool to form an aerosol. Also disclosed, are methods for using these aerosols and kits.

Drug condensation aerosols and kits

Provided herein are methods, devices, kits, and systems for modulating aerosol particle size generated by an aerosol generating device (e.g., electronic nicotine delivery device). Also described herein are methods, devices, kits, and systems for modulating the delivery of aerosol particles generated by an aerosol generating device (e.g., an electronic nicotine delivery device) to the deep lung of a subject.

Aerosol generating device

Provided herein are methods and devices, systems for delivering one or more compounds to a subject. Also described herein are methods and devices for transitioning a smoker to an electronic nicotine delivery device and for smoking or nicotine cessation.

Methods and devices for compound delivery

Inhalation delivery of aerosols containing small particles from a device that forms drug containing aerosols for use in inhalation therapy. A device for delivering drug containing aerosols for inhalation therapy is provided. The device includes a housing and an airway that has a gas/vapor mixing airway. The airway further includes a subassembly, which has a metallic substrate coated on its surface with a composition comprising a drug.

The present application relates to the inhalation delivery of aerosols containing small particles. Specifically, it relates to a method of forming an aerosol for use in inhalation therapy. The method involves: (a) heating a substrate coated with a composition of a drug to form a vapor, wherein the coated composition is in the form of a film less than 10&#x3bc; thick; and, (b) allowing the vapor to cool, thereby forming an aerosol, which is used in inhalation therapy. In another aspect, a method of forming an aerosol for use in inhalation therapy is provided, wherein the method involves: (a) heating a substrate coated with a composition of a drug to form a vapor in less than 100 milliseconds, wherein the vapor has a mass greater than 0.1 mg; and, (b) allowing the vapor to cool, thereby forming an aerosol, which is used in inhalation therapy.

Method of forming an aerosol for inhalation delivery

A method and device are provided to generate an aerosol having a desired particle sizes, i.e., from molecular to about 10 microns, which can be used to effectively deliver a physiologically active compound to organs and tissues such as the lung, eye, mucosa and skin. The aerosol is formed through vaporization of the compound while mixing the resulting vapor with a gas, in a ratio, to form the desired particle size when a stable concentration of particles in the gas is reached.

Aerosol generating method and device

The present invention provides novel condensation aerosols for the treatment of disease and/or intermittent or acute conditions. These condensation aerosols have little or no pyrolysis degradation products and are characterized by having an MMAD of between 1-3 microns. These aerosols are made by rapidly heating a substrate coated with a thin film of drug having a thickness of between 0.05 and 20 &#x3bc;m, while passing a gas over the film, to form particles of a desirable particle size for inhalation. Kits comprising a drug and a device for producing a condensation aerosol are also provided, wherein the device, has an element for heating the drug which is coated as a film on the substrate and contains a therapeutically effective dose of a drug when the drug is administered in aerosol form, and an element allowing the vapor to cool to form an aerosol. Methods for use are also disclosed.

The present invention relates to the inhalation delivery of aerosols containing small particles. Specifically, it relates to a method of forming an aerosol for use in inhalation therapy. The method involves: (a) heating a substrate coated with a composition comprising a drug to form a vapor, wherein the coated composition is in the form of a film less than 10&#x3bc; thick; and, (b) allowing the vapor to cool, thereby forming an aerosol, which is used in inhalation therapy. In another aspect, a method of forming an aerosol for use in inhalation therapy is provided, wherein the method comprises: (a) heating a substrate coated with a composition comprising a drug to form a vapor in less than 100 milliseconds, wherein the vapor has a mass greater than 0.1 mg; and, (b) allowing the vapor to cool, thereby forming an aerosol, which is used in inhalation therapy.

Described herein are respiratory drug condensation aerosols and methods of making and using them. Kits for delivering condensation aerosols are also described. The respiratory drug aerosols typically comprise respiratory drug condensation aerosol particles. In some variations the respiratory drug compound is selected from the group consisting of &#x3b2;-adrenergics, methylxanthines, anticholinergics, corticosteroids, mediator-release inhibitors, anti-leukotriene drugs, asthma inhibitors, asthma antagonists, anti-endothelin drugs, prostacyclin drugs, ion channel or pump inhibitors, enhancers, or modulators and pharmaceutically acceptable analogs, derivatives, and mixtures thereof. Methods of treating a respiratory ailment using the described aerosols are also described. In general, the methods typically comprise the step of administering a therapeutically effective amount of respiratory drug condensation aerosol to a person with a respiratory ailment. Methods of forming a respiratory drug condensation aerosol are also described. The methods comprise the steps of vaporizing and condensing a respiratory drug composition.

Respiratory drug condensation aerosols and methods of making and using them

The present invention relates to the inhalation delivery of aerosols containing small particles. Specifically, it relates to a method of forming an aerosol for use in inhalation therapy. In a method aspect of the present invention, a method of forming an aerosol for use in inhalation therapy is provided. The method involves the following steps: (a) heating a substrate coated with a composition comprising a drug at a rate greater than 1000&#xb0; C./s, thereby forming an vapor; and, (b) allowing the vapor to cool, thereby forming an aerosol, which is used in inhalation therapy. In another method aspect of the present invention, a method of forming an aerosol for use in inhalation therapy is provided. The method involves the following steps: (a) heating a substrate coated with a composition comprising a drug to form a vapor, wherein the coated composition is in the form of a film less than 10&#x3bc; thick; and, (b) allowing the vapor to cool, thereby forming an aerosol, which is used in inhalation therapy. In another method aspect of the present invention, a method of forming an aerosol for use in inhalation therapy is provided. The method involves the following steps: (a) heating a substrate coated with a composition comprising a drug to form a vapor in less than 100 milliseconds, wherein the vapor has a mass greater than 0.1 mg; and, (b) allowing the vapor to cool, thereby forming an aerosol, which is used in inhalation therapy.

Growing community of inventors

Walnut Creek, CA, United States of America

Peter Lloyd